Daniel S. Lorrain - 11 Feb 2026 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Signature
/s/ Peter Slover, Attorney-in-Fact
Issuer symbol
CTNM
Transactions as of
11 Feb 2026
Net transactions value
-$5,996
Form type
4
Filing time
13 Feb 2026, 16:26:06 UTC
Previous filing
05 Feb 2026
Next filing
20 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lorrain Daniel S. Chief Scientific Officer 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO /s/ Peter Slover, Attorney-in-Fact 13 Feb 2026 0001861550

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTNM Class A Common Stock Options Exercise $404 +400 +0.26% $1.01 156,452 11 Feb 2026 Direct F1
transaction CTNM Class A Common Stock Sale $6,400 -400 -0.26% $16.00 156,052 11 Feb 2026 Direct F1
holding CTNM Class A Common Stock 6,842 11 Feb 2026 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTNM Stock Option (right to buy) Options Exercise $0 -400 -0.53% $0.000000 75,530 11 Feb 2026 Class A Common Stock 400 $1.01 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
F2 The stock options are fully vested and exercisable.